Can tigecycline overuse lower a patient's chance of survival?

Yes—in some situations, overuse of tigecycline can lower survival (or increase mortality).

Why this can happen

Tigecycline has a boxed warning from the FDA indicating that it is associated with higher all-cause mortality compared with some alternatives. This signal has shown up in multiple clinical trials, especially in hospital-acquired/infections and complicated intra-abdominal infections where patients may be sicker or when an effective alternative exists.

What “overuse” means in practice

Overuse could involve using tigecycline when:

• A safer or more effective alternative would likely work
• It’s used for infections where tigecycline’s efficacy is uncertain relative to other agents
• It’s used as “last-line” therapy too early, without clear indications

Important nuance

This doesn’t mean tigecycline always reduces survival in every patient or every infection. The increased mortality signal depends on:

• Indication (what type of infection)
• Comparator antibiotics in studies
• Severity and patient factors
• Dosing/treatment appropriateness

If you’re asking for a specific case

If this question is about a particular patient, tell me (if you can) the infection type, setting (e.g., ICU, hospital-acquired), culture results/organisms, and what alternative options were considered. I can help interpret how the survival data applies to that scenario.